Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series

Rhea-AI Summary

Black Diamond Therapeutics announced that its CEO, David M. Epstein, will present at the BMO Biopharma Spotlight Series on February 18, 2021, at 11:50 AM ET. The focus will be on innovative protein technologies. The presentation can be accessed via a live webcast on the company's investor relations page, with a replay available for three weeks. Black Diamond is known for pioneering tumor-agnostic therapies targeting genetically defined cancers using their unique MAP platform, which identifies oncogenic mutations across tumor types.

CAMBRIDGE, Mass. and NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present at the BMO Biopharma Spotlight Series on Thursday, February 18, 2021 at 11:50 AM ET. Dr. Epstein’s presentation will be featured in the session entitled “Company Spotlights: Novel Approaches to Advance Protein Technologies.”

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

FAQ

When is David M. Epstein's presentation at the BMO Biopharma Spotlight Series?

David M. Epstein's presentation is scheduled for February 18, 2021, at 11:50 AM ET.

How can I watch the Black Diamond Therapeutics presentation?

You can watch the presentation live through the investor relations section of Black Diamond Therapeutics' website.

What is the focus of the upcoming presentation by Black Diamond Therapeutics?

The presentation will focus on novel approaches to advance protein technologies.

What is the MAP platform of Black Diamond Therapeutics?

The MAP platform is a proprietary technology designed to analyze genetic data to develop small molecule therapies targeting specific mutation families across various cancers.

How long will the presentation replay be available?

The replay of the presentation will be available for three weeks on the company's website.